De Benedetti V M, Radice P, Mondini P, Spatti G, Conti A, Illeni M T, Caligo M A, Cipollini G, Bevilaqua G, Pilotti S, Pierotti M A
Division of Experimental Oncology A, University of Pisa, Italy.
Oncogene. 1996 Sep 19;13(6):1353-7.
The most common mutations in the familial breast and ovarian cancer susceptibility gene BRCA1 are frameshift and nonsense mutations, which lead to the synthesis of truncated proteins. On this ground, we have analysed BRCA1 exon 11, which includes about 61% of coding region, in germline DNA from 70 Italian breast and/or ovarian cancer patients, using the protein truncation test (PTT). BRCA1 mutations were identified in nine of 29 (approximately 31%) patients with a family history of cancer and in three of 41 (approximately 7%) women with early-onset breast carcinomas, and were subsequently characterized by sequence analysis. In addition, BRCA1 mutations were also detected in six affected relatives of two positive index cases. The observed frequencies of mutations were not significantly different from those expected on the basis of the phenotypic characteristics of patients and their families, indicating that PTT is a rapid and sensitive method that can be used for a first BRCA1 mutational screening. The histological findings in BRCA1 mutated cases showed that eight of nine (approximately 89%) breast carcinomas were of grade III and nine of 9 (100%) ovarian carcinomas were of the endometrioid type (eight of grade III and one of grade II). This suggests that specific histological characteristics may represent additional criteria for selection of cases eligible to BRCA1 mutational analysis.
家族性乳腺癌和卵巢癌易感基因BRCA1中最常见的突变是移码突变和无义突变,这些突变会导致截短蛋白的合成。基于此,我们使用蛋白截短试验(PTT)分析了70例意大利乳腺癌和/或卵巢癌患者生殖系DNA中的BRCA1第11外显子,该外显子包含约61%的编码区。在29例(约31%)有癌症家族史的患者中有9例检测到BRCA1突变,在41例(约7%)早发性乳腺癌女性中有3例检测到BRCA1突变,随后通过序列分析对这些突变进行了特征鉴定。此外,在2例阳性索引病例的6名受影响亲属中也检测到了BRCA1突变。观察到的突变频率与根据患者及其家族的表型特征预期的频率没有显著差异,这表明PTT是一种快速且灵敏的方法,可用于首次BRCA1突变筛查。BRCA1突变病例的组织学检查结果显示,9例乳腺癌中有8例(约89%)为III级,9例卵巢癌均为子宫内膜样类型(8例为III级,1例为II级)。这表明特定的组织学特征可能代表了选择适合进行BRCA1突变分析病例的额外标准。